Zobrazeno 1 - 10
of 903
pro vyhledávání: '"35"'
Autor:
Francisco Lastiri, Santiago Pavlovsky
Publikováno v:
Clinical lymphoma. 5(2)
The purpose of this study was to evaluate the trends in complete remission (CR) rate, disease-free survival (DFS), and overall survival (OS) through 35 years of Grupo Argentino de Tratamiento de la Leucemia Aguda (GATLA) clinical trials. A total of 1
Autor:
Atsuko Tsukamoto, Fumio Kawano, Shoichi Nagakura, Yoshiko Inoue, Toshiro Kawakita, Takahiro Matsui, Michihiro Hidaka, Tetsuyuki Kiyokawa, Tatsunori Sakai, Shigeki Takemoto
Publikováno v:
Blood. 110:5037-5037
Adult T cell leukemia/lymphoma (ATL) has a high incident in Japanese. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) against ATL made the patients’ survival longer than chemotherapy alone. Actually, some of them became long survivor
Publikováno v:
American journal of clinical pathology. 66(4)
Thirty-five patients with rhabdomyosarcoma were treated at the Children's Hospital Medical Center from 1953 to 1973. Factors important in diagnosis and prognosis included age, sex, site, stage of tumor, and specific pathologic type. Effects that surg
Autor:
Takeshi Yanagi, Yoshiyuki Ozawa, Takuhito Kondo, Yuta Shibamoto, Taro Murai, Chikao Sugie, Satoshi Ishikura, Akifumi Miyakawa
Publikováno v:
Journal of Radiation Research
Definitive chemoradiotherapy (dCRT) is the standard treatment for unresectable esophageal cancer. Induction chemotherapy has been actively investigated for borderline-resectable and unresectable disease, but the superiority over dCRT has yet to be co
Autor:
Huseyin Mertsoylu, Mehmet Artac, Celaletdin Camci, Nuriye Ozdemir, Mehmet Ali Nahit Sendur, Arzu Baygul, Bulent Karabulut, Huseyin Abali, Burce Goktas, Suayib Yalcin, Berna Oksuzoglu, Burcin Budakoglu, Faysal Dane, Fatma Buğdaycı Başal, Fatih Ozdener, Huseyın Cem Onal
Background: Trastuzumab prolonged the overall survival in patients with advanced gastric cancer with human epidermal growth factor receptor 2 (HER2) overexpression in combination with chemotherapy. In this phase II open-label prospective study, the t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a44f3ebf6a13959f0762867ae06cc75f
https://avesis.gazi.edu.tr/publication/details/c0518f33-e4c6-4042-8712-e074abd00247/oai
https://avesis.gazi.edu.tr/publication/details/c0518f33-e4c6-4042-8712-e074abd00247/oai
Autor:
Jean Rousset, Selima Sellami, François Lucia, Olivier Pradier, Dominique Gouders, Rémi Marianowski, Yves Gobel, Arnaud Uguen, Ronan Abgral, Jean Christophe Leclere, Ulrike Schick
Publikováno v:
Acta Otorhinolaryngologica Italica
To report outcome and predictive factors in patients with N3 (6 cm) non-metastatic locally advanced head and neck squamous cell carcinoma (LAHNSCC) treated with a conservative approach or with initial surgery.104 patients were included: 69 treated wi
Autor:
Maximilian Hochmair, Sang-We Kim, Frank G. Haluska, Edward S. Kim, Luis Paz-Ares Rodríguez, Karen L. Reckamp, Howard West, Egbert F. Smit, William M. Reichmann, David Kerstein, D. Ross Camidge, Rudolf M. Huber, Scott N. Gettinger, Karin Holmskov Hansen, Natasha B. Leighl, Marcello Tiseo, Corey J. Langer, Myung-Ju Ahn, Dong Wan Kim, Harry J.M. Groen
Publikováno v:
Kim, D W, Tiseo, M, Ahn, M J, Reckamp, K L, Hansen, K H, Kim, S W, Huber, R M, West, H L, Groen, H J M, Hochmair, M J, Leighl, N B, Gettinger, S N, Langer, C J, Rodríguez, L G P A, Smit, E F, Kim, E S, Reichmann, W, Haluska, F G, Kerstein, D & Camidge, D R 2017, ' Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer : A randomized, multicenter phase II trial ', Journal of Clinical Oncology, vol. 35, no. 22, pp. 2490-2498 . https://doi.org/10.1200/JCO.2016.71.5904
Journal of Clinical Oncology, 35(22), 2490-2498. AMER SOC CLINICAL ONCOLOGY
Kim, D-W, Tiseo, M, Ahn, M-J, Reckamp, K L, Hansen, K H, Kim, S-W, Huber, R M, West, H L, Groen, H J M, Hochmair, M J, Leighl, N B, Gettinger, S N, Langer, C J, Paz-Ares Rodríguez, L G, Smit, E F, Kim, E S, Reichmann, W, Haluska, F G, Kerstein, D & Camidge, D R 2017, ' Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer : A Randomized, Multicenter Phase II Trial ', Journal of Clinical Oncology, vol. 35, no. 22, pp. 2490-2498 . https://doi.org/10.1200/JCO.2016.71.5904
Journal of Clinical Oncology, 35(22), 2490-2498. American Society of Clinical Oncology
Journal of Clinical Oncology, 35(22), 2490-2498. AMER SOC CLINICAL ONCOLOGY
Kim, D-W, Tiseo, M, Ahn, M-J, Reckamp, K L, Hansen, K H, Kim, S-W, Huber, R M, West, H L, Groen, H J M, Hochmair, M J, Leighl, N B, Gettinger, S N, Langer, C J, Paz-Ares Rodríguez, L G, Smit, E F, Kim, E S, Reichmann, W, Haluska, F G, Kerstein, D & Camidge, D R 2017, ' Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer : A Randomized, Multicenter Phase II Trial ', Journal of Clinical Oncology, vol. 35, no. 22, pp. 2490-2498 . https://doi.org/10.1200/JCO.2016.71.5904
Journal of Clinical Oncology, 35(22), 2490-2498. American Society of Clinical Oncology
Purpose Most crizotinib-treated patients with anaplastic lymphoma kinase gene ( ALK)–rearranged non–small-cell lung cancer (ALK-positive NSCLC) eventually experience disease progression. We evaluated two regimens of brigatinib, an investigational
Autor:
Cheng-Yen Chuang, Chen-Fa Chang, Hui-Ling Yeh, Jai-Fu Lin, Jin-Ching Lin, Chung-Ping Hsu, Jing-Wen Huang
Publikováno v:
Journal of the Chinese Medical Association, Vol 80, Iss 7, Pp 401-407 (2017)
Background We investigated preoperative concurrent chemoradiotherapy (CCRT) with oxaliplatin for locally advanced, potentially operative esophageal cancer in this Phase II study. Methods Between October 2009 and October 2011, 35 consecutive patients
Autor:
Michael R. Boland, Aoife Lowery, R. S. Prichard, Terri P. McVeigh, Cecily Quinn, Michael J. Kerin, Emma McDermott, N. O'Flaherty, Maccon M. Keane, G. Gullo
Publikováno v:
BJS Open. 1:39-45
Background Optimal evaluation and management of the axilla following neoadjuvant chemotherapy (NAC) in patients with node-positive breast cancer remains controversial. The aim of this study was to examine the impact of receptor phenotype in patients
Autor:
Kohei Shitara, Akihiro Sato, Toshihiko Doi, Tomohiro Nishina, Kei Muro, Shunji Takahashi, Atsushi Ohtsu, Shogo Nomura, Hideaki Bando, Kensei Yamaguchi, Hirofumi Kuno, Hirofumi Yasui
Publikováno v:
European Journal of Cancer. 62:46-53
Aim American phase I studies have reported that the recommended dose of TAS-102 (trifluridine/tipiracil) was 25 mg/m 2 twice a day (b.i.d.), although this schedule did not provide clinically relevant improvements in a phase II study of advanced gastr